NCT04816942 is a Phase 3 clinical trial of Convalescent Plasma in Convalescent Plasma, sponsored by Ministry of Health and Population, Egypt.

Who is sponsoring NCT04816942?

NCT04816942 is sponsored by Ministry of Health and Population, Egypt.

What drugs are being tested in NCT04816942?

Interventions in NCT04816942: Convalescent Plasma.

What condition does NCT04816942 study?

NCT04816942 studies Convalescent Plasma, Covid19, Immunoglobulins, Plasma, Egypt.

Is NCT04816942 still recruiting?

NCT04816942 is currently completed. Last updated 25 March 2021.

Last reviewed 2021-03-25 · How we verify

NCT04816942

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt

Completed Phase 3 Last updated 25 March 2021

What this trial tests

Phase 3 trial testing Convalescent Plasma in Convalescent Plasma in 102 participants. Completed in 12 October 2020.

Timeline

23 April 2020

Primary endpoint
21 July 2020

12 October 2020

Quick facts

Lead sponsor	Ministry of Health and Population, Egypt
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	102
Start date	23 April 2020
Primary completion	21 July 2020
Estimated completion	12 October 2020
Sites	1 location across Egypt

Drugs / interventions tested

Convalescent Plasma — full drug profile →

Conditions studied

Convalescent Plasma — all drugs for Convalescent Plasma →
Covid19 — all drugs for Covid19 →
Immunoglobulins — all drugs for Immunoglobulins →
Plasma — all drugs for Plasma →

Sponsor

Ministry of Health and Population, Egypt

Who can join

18 and older, any sex, with Convalescent Plasma or Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

One investigational treatment being explored for COVID-19 is the use of convalescent plasma collected from individuals who have recovered from COVID-19 (Refs. 1-4). Convalescent plasma that contains antibodies to severe acute respiratory syndrome coronavirus 2 or SARSCoV-2 (the virus that causes COVID-19) is being studied for administration to patients with COVID-19. Use of convalescent plasma has been studied in outbreaks of other respiratory infections, including the 2003 SARS-CoV-1 epidemic, the 2009-2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic (Refs. 5-7). Although promising, convalescent plasma has not yet been shown to be safe and effective as a treatment for COVID-19. Therefore, it is important to study the safety and efficacy of COVID19 convalescent plasma in clinical trials. This guidance provides recommendations to health care providers and investigators on the administration and study of investigational convalescent plasma collected from individuals who have recovered from COVID-19 (COVID-19 convalescent plasma) during the public health emergency. This guidance also provides recommendations to blood establishments on the collection of COVID-19 convalescent plasma..

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794

Verify or expand the search:

Other trials of Convalescent Plasma

Trials testing the same drug.

NCT04884477 — COVID-19 Infection in Patients Receiving Anti-CD20 Therapy · completed
NCT04539275 — VA CoronavirUs Research and Efficacy Studies-1 · Phase 3 · terminated
NCT04456413 — Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection · Phase 2 · terminated
NCT04558476 — Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation · Phase 2 · completed
NCT04513158 — Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection · Phase 2 · terminated

Other Ministry of Health and Population, Egypt trials

Trials by the same sponsor.

NCT06148805 — Effect of Pilates Exercises and Diaphragm Manual Therapy Techniques in Rotator Cuff Tendinopathy · NA · unknown
NCT06002256 — Mostafa Maged Maneuver in Comparison With Bimanual Uterine Compression to Control Post-partum Hemorrhage · NA · completed
NCT06159959 — Carbetocin in the Prevention of Primary Postpartum Haemorrhage · completed
NCT06801106 — Acapella Versus Lung Flute in Treatment of COPD Patients the Study Aims to Identify the Preference Between the Two Devic · NA · completed
NCT04425707 — Ivermectin In Treatment of COVID 19 Patients · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04816942 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ministry of Health and Population, Egypt
Last refreshed: 25 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04816942.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing